Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are significant invasive disease-free survival benefits in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login